As de-sumoylation is critical for full NLRP3 activation, targeting SENPs may offer new opportunities for treating inflammatory diseases that are caused by aberrant activation of the NLRP3 inflammasome, such as type-II diabetes, gout, and Alzheimer’s disease. The gene discussed is NLRP3; the disease is gout.